Immunodeficiency virus neutralization assay
AssigneeQuality Biological, Inc.
InventorSandra K. Dusing
Life of this patent
Estimating the term…
Abstract
A method for assaying the ability of an antibody to neutralize primary clinical isolates of human immunodeficiency virus (HIV) in primary human lymphocytes comprising the steps of contacting primary human lymphocytes with HIV and an antibody sample to be tested, without preincubating the antibody sample and the virus, culturing the primary human lymphocytes under conditions which allow for HIV replication without removal of the virus inoculum or antibody samples to be tested, and measuring HIV replication in the primary human lymphocytes by one or more of several conventional methods.
Claims19
An immunodeficiency virus neutralization assay, comprising the steps of:
- contacting human lymphocytes with human immunodeficiency virus type 1(HIV-1) and an antibody, with or without premixing of said HIV-1 and said antibody, wherein if said HIV-1 and said antibody are mixed together, the mixture is added to said human lymphocytes less than fifteen minutes after mixing;
- culturing said human lymphocytes under conditions which allow for HIV-1 replication;
- and
- measuring HIV-1 replication in said human lymphocytes.
A human immunodeficiency virus type 1(HIV-1) neutralization assay, comprising the steps of:
- mixing HIV-1 and an antibody together and maintaining the resulting mixture at a temperature less than 6.degree. C. and for a time of less than 15 minutes;
- contacting primary human lymphocytes with the mixture of HIV-1 and an antibody for at least 45 minutes to allow for adsorption between said primary human lymphocytes, said HIV-1 and antibody;
- culturing said primary human lymphocytes under conditions which allow for HIV-1 replication, without washing said primary human lymphocytes;
- and
- measuring HIV-1 replication in said primary human lymphocytes.
An assay for determining the ability of an antibody sample to neutralize primary clinical isolates of human immunodeficiency virus type 1(HIV-1) which comprises the steps of:
- contacting primary human lymphocytes with HIV-1 and an antibody sample to be tested with or without premixing of said HIV-1 and said antibody wherein if said HIV-1 and said antibody are mixed together, the mixture is added to said primary human lymphocytes less than fifteen minutes after mixing;
- culturing the primary human lymphocytes in the continuous presence of both the virus inoculum and the antibody sample to be tested under conditions which allow for HIV-1 replication;
- and
- measuring HIV-1 replication in the primary human lymphocytes.
A method for assaying the ability of an antibody to neutralize primary clinical isolates of the human immunodeficiency virus type 1 (HIV-1), as well as laboratory strains of the virus, in primary human lymphocytes, comprising the steps of:
- contacting primary human lymphocytes with HIV-1 and an antibody sample to be tested with or without premixing of said HIV-1 and said antibody wherein if said HIV-1 and said antibody are mixed together, the mixture is added to said primary human lymphocytes less than fifteen minutes after mixing;
- culturing said primary human lymphocytes under conditions which allow for HIV-1 replication without removal of the unadsorbed virus inoculum or unreacted antibody being tested;
- and
- measuring HIV-1 replication in said primary human lymphocytes.
A human immunodeficiency virus type 1(HIV-1) neutralization assay, comprising the steps of:
- mixing HIV-1 and an antibody and maintaining the mixture at a temperature less than 6.degree. C. until the mixture is contacted with human lymphocytes;
- contacting human lymphocytes with said mixture of HIV-1 and an antibody;
- culturing said human lymphocytes under conditions which allow for HIV-1 replication;
- and
- measuring HIV-1 replication in said human lymphocytes.
Dependencies are inferred from the claim text.